

# Brow Ptosis and Eyelid Repair

**Policy Number:** MP.002.24  
**Effective Date:** October 1, 2024

[Instructions for Use](#)

Table of Contents	Page
<a href="#">Application</a>	1
<a href="#">Coverage Rationale</a>	1
<a href="#">Medical Records Documentation Used for Reviews</a>	2
<a href="#">Definitions</a>	3
<a href="#">Applicable Codes</a>	3
<a href="#">Benefit Considerations</a>	4
<a href="#">Clinical Evidence</a>	4
<a href="#">U.S. Food and Drug Administration</a>	7
<a href="#">References</a>	7
<a href="#">Policy History/Revision Information</a>	8
<a href="#">Instructions for Use</a>	8

## Related Commercial/Individual Exchange Policy

- [Cosmetic and Reconstructive Procedures](#)
- [Gender Dysphoria Treatment](#)

## Community Plan Policy

- [Brow Ptosis and Eyelid Repair](#)

## Medicare Advantage Policy

- [Blepharoplasty and Related Procedures](#)

## Application

### UnitedHealthcare Commercial

This Medical Policy applies to all UnitedHealthcare Commercial benefit plans.

### UnitedHealthcare Individual Exchange

This Medical Policy applies to Individual Exchange benefit plans in all states except for Colorado.

## Coverage Rationale

[See Benefit Considerations](#)

**Note:** The InterQual® criteria below only applies to persons 18 years of age and older.

**Brow ptosis repair and repair of the eyelid are considered reconstructive and medically necessary in certain circumstances.** For medical necessity clinical coverage criteria, refer to the InterQual® CP: Procedures:

- Blepharoplasty
- Ectropion Repair
- Entropion Repair
- Eyelid Lesion Excision, +/- Reconstruction
- Eyelid Reconstruction
- Ptosis Repair

[Click here to view the InterQual® criteria.](#)

**Note:** If multiple procedures are requested, criteria for each individual procedure must be met.

**Internal Browpexy** for any condition is considered cosmetic and not medically necessary.

**Eyelid surgery for correction of [Lagophthalmos](#) is considered reconstructive and medically necessary when the upper eyelid is not providing complete closure to the eye, resulting in dryness and other complications.**

**Lid retraction surgery (CPT code 67911) is considered reconstructive and medically necessary when all of the following criteria are present:**

- Other causes have been eliminated as the reason for the lid retraction such as use of dilating eye drops, glaucoma medications; and
- There is a functional impairment (e.g., dry eyes, pain/discomfort, tearing, blurred vision); and
- Tried and failed conservative treatments; and
- In cases of thyroid eye disease, two or more Hertel measurements at least 6 months apart with the same base measurements are unchanged

**Canthoplasty/Canthopexy (CPT codes 21280, 21282, and 67950) are considered reconstructive and medically necessary when all of the following criteria are present:**

- There is a functional impairment; and
- Repair of ectropion or entropion will not correct condition; and
- At least one of the following is present:
  - Epiphora (excess tearing) not resolved by conservative measures; or
  - Corneal dryness unresponsive to lubricants; or
  - Corneal ulcer

**Repair of Floppy Eyelid Syndrome (FES) (CPT codes 67961 and 67966) is considered reconstructive and medically necessary when all of the following are present and have been documented and confirmed by history and examination:**

- Subjective symptoms must include eyelids spontaneously "flipping over" when the member sleeps due to rubbing on the pillow, and one of the following:
  - Eye pain or discomfort; or
  - Excess tearing; or
  - Eye irritation, ocular redness, and discharge
- Physical examination that documents all of the following:
  - Both of the following:
    - Eyelash ptosis; and
    - Significant upper eyelid laxityand
  - One of the following:
    - Presence of giant papillary conjunctivitis (GPC); or
    - Corneal findings such as one of the following:
      - Superficial punctate erosions (SPK); or
      - Corneal abrasion (documentation of a history of corneal abrasion or recurrent erosion syndrome is considered sufficient); or
      - Microbial keratitis
- Clear, high-quality, clinical photographs that clearly document Floppy Eyelid Syndrome and demonstrate both of the following:
  - Lids must be everted in the photographs; and
  - Conjunctival surface (underbelly) of the lids must be clearly visible
- Documentation that conservative treatment has been tried and failed; examples may include:
  - Ocular lubricants both drops (daytime) and ointments (bedtime); or
  - Short trial of antihistamines; or
  - Topical steroid drops; or
  - Eye shield and/or taping the lids at bedtime
- Infections of the eye have been ruled out; examples may include:
  - Allergic conjunctivitis
  - Atopic keratoconjunctivitis
  - Blepharitis
  - Contact lens (CL) complication [e.g., Giant Papillary Conjunctivitis (GPC)]
  - Superior limbic keratoconjunctivitis (SLK)

## Medical Records Documentation Used for Reviews

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. Medical records documentation may be required to assess whether the

member meets the clinical criteria for coverage but does not guarantee coverage of the service requested; refer to the protocol titled [Medical Records Documentation Used for Reviews](#).

## Definitions

The following definitions may not apply to all plans. Refer to the member specific benefit plan document for applicable definitions.

**Canthopexy:** A surgical technique for lid malposition that involves securing the lateral retinaculum to the periosteum of the superolateral orbital rim with a suture (Rizvi 2010).

**Canthoplasty:** A procedure that is indicated for a variety of eyelid conditions. It is applicable to any disruption to the normal architecture of the canthus which can lead to negative functional sequelae (AAO 2023).

**Floppy Eyelid Syndrome (FES):** A frequent eyelid disorder characterized by eyelid laxity that determines a spontaneous eyelid eversion during sleep associated with chronic papillary conjunctivitis and systemic diseases (DeGregorio, 2021).

**Internal Browpexy:** A minimally invasive technique to provide stabilization and subtle elevation of the lateral brow (Karimi et al., 2020).

**Lagophthalmos:** The inability to close the eyelids completely. A portion of the eye remains open during a blink and during sleep and is subject to damage from exposure (AAO Exposure Keratopathy, 2024).

**Marginal Reflex Distance -1 (MRD-1):** The measurement in millimeters from the light reflex on the patient’s cornea to the upper eyelid margin with the patient gazing in the primary position. MRD1 is used to indicate degree of ptosis or retraction (AAO 2023).

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

**Note:** The following codes may be cosmetic; review is required to determine if considered cosmetic or reconstructive.

CPT Code	Description
<b>Blepharoplasty (Lower and Upper Eyelid)</b>	
15820	Blepharoplasty, lower eyelid
15821	Blepharoplasty, lower eyelid; with extensive herniated fat pad
15822	Blepharoplasty, upper eyelid;
15823	Blepharoplasty, upper eyelid; with excessive skin weighting down lid
<b>Brow Ptosis Repair</b>	
67900	Repair of brow ptosis (supraciliary, mid-forehead or coronal approach)
<b>Upper Eyelid Blepharoptosis Repair</b>	
67901	Repair of blepharoptosis; frontalis muscle technique with suture or other material (e.g., banked fascia)
67902	Repair of blepharoptosis; frontalis muscle technique with autologous fascial sling (includes obtaining fascia)
67903	Repair of blepharoptosis; (tarso) levator resection or advancement, internal approach
67904	Repair of blepharoptosis; (tarso) levator resection or advancement, external approach
67906	Repair of blepharoptosis; superior rectus technique with fascial sling (includes obtaining fascia)
67908	Repair of blepharoptosis; conjunctivo-tarso-Muller’s muscle-levator resection (e.g., Fasanella-Servat type)

CPT Code	Description
<b>Upper Eyelid Blepharoptosis Repair</b>	
67909	Reduction of overcorrection of ptosis
<b>Lid Retraction</b>	
67911	Correction of lid retraction
<b>Lagophthalmos</b>	
67912	Correction of lagophthalmos, with implantation of upper eyelid lid load (e.g., gold weight)
<b>Ectropion and Entropion</b>	
67914	Repair of ectropion; suture
67915	Repair of ectropion; thermocauterization
67916	Repair of ectropion; excision tarsal wedge
67917	Repair of ectropion; extensive (e.g., tarsal strip operations)
67921	Repair of entropion; suture
67922	Repair of entropion; thermocauterization
67923	Repair of entropion; excision tarsal wedge
67924	Repair of entropion; extensive (e.g., tarsal strip or capsulopalpebral fascia repairs operation)
<b>Canthoplasty/Canthopexy</b>	
21280	Medial canthopexy (separate procedure)
21282	Lateral canthopexy
67950	Canthoplasty (reconstruction of canthus)
67961	Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; up to one-fourth of lid margin
67966	Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; over one-fourth of lid margin
<b>Floppy Eyelid Syndrome</b>	
67961	Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; up to one-fourth of lid margin
67966	Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; over one-fourth of lid margin

*CPT® is a registered trademark of the American Medical Association*

## Benefit Considerations

Some states require benefit coverage for services that UnitedHealthcare considers cosmetic procedures, such as repair of external congenital anomalies in the absence of a functional impairment. Refer to the member specific benefit plan document.

UnitedHealthcare excludes cosmetic procedures from coverage, including but not limited to the following:

- Procedures that correct an anatomical congenital anomaly without improving or restoring physiologic function are considered cosmetic procedures. The fact that a Covered Person may suffer psychological consequences or socially avoidant behavior as a result of an injury, sickness, or congenital anomaly does not classify surgery (or other procedures done to relieve such consequences or behavior) as a reconstructive procedure.

## Clinical Evidence

### Internal Browpexy

An internal browpexy is best for mild brow ptosis, which is considered cosmetic. It is difficult to generate a substantial amount of elevation using this technique (Shaw and Phelps, 2020).

Brow Ptosis and Eyelid Repair

UnitedHealthcare Commercial and Individual Exchange Medical Policy

Page 4 of 9

Effective 10/01/2024

**Proprietary Information of UnitedHealthcare. Copyright 2024 United HealthCare Services, Inc.**

In a 2023 objective comparison of eyebrow position following internal and external Browpexy, Huang et al. retrospectively reviewed the cases of 68 patients, mostly females, who underwent either internal browpexy (39), external browpexy (9) or upper eyelid skin excision alone (20). Photographs were taken before, immediately after surgery, then at one week, 1-3 months, 4-6 months, and 7-12 months. Brow height changes were measured using the ImageJ biological measuring program and compared among the three groups. The results showed both internal and external browpexy provided improvement within 3 months of surgery, however outcomes for those treated with an external browpexy had better brow-lift outcomes across the entire brow than did internal browpexy. The authors concluded that external browpexy is a better choice for those with severe whole brow ptosis, and internal browpexy is recommended for patients with mild ptosis. This retrospective observational study is limited by a small number of participants and a lack of randomization. Additionally, uneven distribution Furthermore, most patients were lost to follow up so longer term data is not available. Further high quality research is needed to validate these findings.

## **Floppy Eyelid Syndrome (FES)**

There is no diagnostic test for FES. It is a clinical diagnosis based on history, symptoms, and systemic associations, including obstructive sleep apnea (OSA) and keratoconus as well as other sequelae of OSA and morbid obesity. Patients with this condition should be managed with an internal medicine team and a sleep disorder specialist. Addressing underlying obesity, OSA and avoiding sleeping in a prone position may improve symptoms. If there is minimal response to medical treatment, surgical procedures such as horizontal eyelid shortening can help to relieve ocular symptoms and provide good functional and cosmetic results. Surgery should be considered in significantly symptomatic patients after controlling ocular surface disease and optimizing medical status (AAO, 2023).

Cheong et al. (2022) conducted a systematic review and meta-analysis to investigate the relationship between obstructive sleep apnea (OSA) and FES. The systematic review included 12 studies, nine of which were included in the meta-analysis, with a total of 1,109 individuals. The analysis of the data determined a significant association between OSA and FES (OR = 1.89, 95% CI = 1.27-2.83, I<sup>2</sup> = 44%). Upon further investigation the study determined the more severe the OSA was, the higher the risk of developing FES. Patients with severe OSA had the highest risk of developing FES (OR = 3.06, 95% CI = 1.62-5.78, I<sup>2</sup> = 0%), followed by moderate OSA (OR = 2.53, 95% CI = 1.29-4.97, I<sup>2</sup> = 0%), and patients with mild OSA had the lowest risk (OR = 1.76, 95% CI = 0.85-3.62, I<sup>2</sup> = 0%). The authors concluded there was a positive association between OSA and FES with increasing severity of OSA correlating with significantly higher risk of FES. Limitations in the study were important covariates such as age, gender and body mass index were not adjusted. The authors recommend more longitudinal studies with sufficient duration of follow-up to better characterize the relationship between OSA and FES.

Acar et al. (2021) conducted a randomized controlled trial (RCT) of 51 patients with obstructive sleep apnea hypopnea syndrome (OSAHS) to assess the long-term effects of positive airway pressure (PAP) therapy on the eyelid and the ocular surface. Over a period of 18 months patients were treated with PAP then the scores were compared for the pre- and post-PAP values for eye examination which included the presence of FES, ocular surface disease index (OSDI) questionnaire results, Schirmer I test, tear film breakup time (TBUT), and corneal staining. The presence of FES before and after PAP was 56.9% and 74.5% (p < 0.01). FES stage was determined as 1.41 ±0.98 before PAP and 0.78 ±0.78 after PAP (p < 0.01). Pre-PAP and post-PAP ocular surface disease index OSDI results were 47.79 ±21.04 and 42.17 ±19.97, (p < 0.01). Schirmer values before and after PAP were 7.23 ±1.95 and 8.49 ±1.79 mm, (p < 0.01). TBUT values before and after PAP were 7.11 ±1.82 and 8.68 ±1.76 seconds, (p < 0.01). Scores of the corneal staining stages before and after PAP were 1.05 ±0.75 and 0.68 ±0.54, (p < 0.01). The authors concluded OSAHS was associated with low Schirmer and TBUT values, high scores on the OSDI questionnaire, and high corneal staining. Normal sleep patterns returned after appropriate use of PAP along with relief of systemic findings and ocular surface problems. The authors believe long term use of PAP (at least one year) improves FES and overcomes the problem of ocular irritation that occurs in the early stage of PAP therapy. Limitations of the study include lack of blinding when performing the ocular screenings and small sample size.

## **Lagophthalmos**

Proper eyelid closure and a normal blink reflex are essential to maintaining a stable tear film and a healthy corneal surface. Patients affected with lagophthalmos are unable to fully close their eyelids, and they may describe symptoms of dry and irritated eyes. Common morbidities of lagophthalmos are corneal exposure and subsequent keratopathy, which may progress to corneal ulceration and infectious keratitis. It is important to recognize lagophthalmos early in the patient's course and begin treatment as soon as possible. The choice of therapy requires an understanding of both the etiology and expected duration of the lagophthalmos. (AAO, 2008)

## Lid Retraction Surgery

Upper eyelid retraction is defined by abnormally high resting position of the upper lid. This produces visible sclera between the eyelid margin and corneal limbus, which produces the appearance of a stare with an accompanying illusion of exophthalmos. Eyelid retraction can lead to lagophthalmos and exposure keratitis, which can cause mild ocular surface irritation to vision-threatening corneal decompensation. The most common causes of upper eyelid retraction include thyroid eye disease, recession of superior rectus muscle, and contralateral ptosis (AAO, 2023).

Lower eyelid retraction is a malposition of the lower eyelid in which the lid margin is displaced inferiorly resulting in increased exposure of the surface of the eye to the environment. This can present with dry eye symptoms and can lead to exposure keratitis, corneal ulcer, and even corneal scarring. It can present unilaterally or bilaterally, depending on the etiology and most frequently presents due to thyroid eye disease. Mild cases may be managed with ocular surface lubrication and more severe cases with dermal filler or surgery (AAO, 2024).

Hoang T et al. (2021) completed the 2022 update on clinical management of Graves' Disease and thyroid eye disease (TED). General treatment of patients with TED includes reversal of hyperthyroidism, monitoring for and prompt treatment of hypothyroidism, and cessation of smoking, if applicable. First-line therapy for individuals with moderate to severe TED would include intravenous glucocorticoids. Surgery for TED is typically performed either emergently, such as for optic neuropathy, globe subluxation, or corneal thinning/perforation due to exposure keratopathy, or for rehabilitation after the disease has run its active course. Eyelid changes due to TED are common and include upper and lower eyelid retraction and eyelid fat compartment expansion. Eyelid retraction surgery is aimed at lowering the upper eyelid and raising the lower eyelid to correct the "thyroid stare" appearance. Eyelid contouring is targeted to restore the natural height and contour of the eyelid, including decreasing the fat compartment expansion and minimizing the temporal flare, which occur as part of the disease state. Eyelid surgery is typically the last step in the rehabilitation of the patient's appearance. The total time between onset of TED to the final eyelid surgery can span several years.

Hodgson and Rajaii (2020) conducted a systematic review on the pathophysiology and treatment options for the management of thyroid associated orbitopathy (TAO). TAO also known as Graves' orbitopathy (GO) and thyroid eye disease (TED) is associated with distinct clinical features, including upper eyelid retraction, restrictive strabismus, and proptosis. Moderate to severe TAO is defined as lid retraction > 2 mm, exophthalmos > 3 mm, moderate to severe soft tissue involvement, and presence of diplopia. Sight-threatening TAO is defined as presence of direct optic neuropathy or corneal breakdown. Rehabilitative surgical options include orbital decompression for severe proptosis, strabismus surgery, followed by upper and lower lid retraction surgery. The authors concluded surgical management is required in cases of severe vision-threatening disease that is refractory to medical management, and as restorative treatment when the disease is inactive and clinical measurements are stable. Limitations to the study are small sample sizes and non-randomized studies.

## Medial and Lateral Canthoplasty/Canthopexy

### *Clinical Practice Guidelines*

#### **American Academy of Ophthalmology (AAO) 2008**

- Indications for functional canthoplasty:
  - Congenital and involutional entropion
  - Congenital, involutional and cicatricial ectropion
  - Lid laxity (seen with anophthalmos or enophthalmos, and facial nerve palsy)
  - Canthal dystopia
  - Exposure keratopathy
  - Epiphora
  - Vertical eyelid retraction [due to trauma, after blepharoplasty, with thyroid eye disease (contraindicated if significant proptosis)]
  - Repair after iatrogenic damage or trauma
  - In conjunction with blepharoplasty:
    - To prevent ectropion or eyelid retraction
    - Festoons
  - Delayed repair resulting in rounding of the canthus
  - Telecanthus
  - Congenital malposition or occlusion of the visual field
  - Absent naso-orbital valley
  - With lateral orbitotomy:
    - In orbital decompression
    - Removal of orbital tumors



# U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Brow ptosis repair and eyelid repair are procedures and, therefore, not regulated by the FDA. However, devices and instruments used during the surgery may require FDA approval. Refer to the following website for additional information: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmnm.cfm>. (Accessed March 25, 2024)

## References

- Acar M, Firat H, Yuceede M, et al. Long-term effects of PAP on ocular surface in obstructive sleep apnea syndrome. *Can J Ophthalmol*. 2014 Apr;49(2):217-21.
- American Academy of Ophthalmology (AAO). Lagophthalmos Evaluation and Treatment. April 2008. Available at: <https://www.aao.org/eyenet/article/lagophthalmos-evaluation-treatment>. Accessed April 16, 2024.
- American Academy of Ophthalmology (AAO). EyeWiki®. Canthoplasty. December 2023.
- American Academy of Ophthalmology (AAO). EyeWiki®. Exposure Keratopathy. March 2024.
- American Academy of Ophthalmology (AAO). EyeWiki®. Floppy Eyelid Syndrome. February 2024.
- American Academy of Ophthalmology (AAO). EyeWiki®. Lower Eyelid Retraction. April 2024.
- American Academy of Ophthalmology (AAO). EyeWiki®. Margin to Reflex Distance 1,2,3. October 2023.
- American Academy of Ophthalmology (AAO). EyeWiki®. Upper Eyelid Retraction. December 2023.
- Centers for Disease Control and Prevention. Disability and Health Promotion. Disability and Health Overview. September 2020. Available at: <https://www.cdc.gov/ncbddd/disabilityandhealth/disability.html>. Accessed March 25, 2024.
- Chambe J, Laib S, Hubbard J, et al. Floppy eyelid syndrome is associated with obstructive sleep apnoea: a prospective study on 127 patients. *J Sleep Res*. 2012 Jun;21(3):308-15.
- Cheong AJY, Ho OTW, Wang SKX, et al. Association between obstructive sleep apnea and floppy eyelid syndrome: a systematic review and meta-analysis. *Surv Ophthalmol*. 2022 Nov 22:S0039-6257(22)00170-9.
- De Gregorio A, Cerini A, Scala A, et al. Floppy eyelid, an under-diagnosed syndrome: a review of demographics, pathogenesis, and treatment. *Ther Adv Ophthalmol*. 2021 Dec 5;13:25158414211059247.
- Dickinson J, Perros P. Thyroid-associated orbitopathy: who and how to treat. *Endocrinology and Metabolism Clinics*, 2009-06-01, Volume 38, Issue 2, Pages 373-388.
- Fowler AM, Dutton JJ. Floppy eyelid syndrome as a subset of lax eyelid conditions: relationships and clinical relevance (an ASOPRS thesis). *Ophthal Plast Reconstr Surg*. 2010 May-Jun;26(3):195-204.
- Hoang TD, Stocker DJ, Chou EL et al. 2022 update on clinical management of Graves' Disease and thyroid eye disease. *Endocrinology and Metabolism Clinics*. N Am 51 (2022) 1–18.
- Hodgson NM, Rajaii F. Current understanding of the progression and management of thyroid associated orbitopathy: a systematic review. *Ophthalmol Ther*. 2020 Mar;9(1):21-33.
- Huang PJ, Mao SH, Yen CI, et al. Objective comparison of eyebrow position after internal and external browpexy. *Plast Reconstr Surg*. 2023 Sep 1;152(3):414e-423e.
- Karimi N, Kashkouli MB, Sianati H, et al. Techniques of eyebrow lifting: a narrative review. *J Ophthalmic Vis Res*. 2020 Apr 6;15(2):218-235.
- Nerad JA. *Techniques in ophthalmic plastic surgery*. 2<sup>nd</sup> ed. Philadelphia: Elsevier; 2021.
- Periman LM, Sires BS. Floppy eyelid syndrome: a modified surgical technique. *Ophthal Plast Reconstr Surg*. 2002 Sep;18(5):370-2.
- Valenzuela AA, Sullivan TJ. Medial upper eyelid shortening to correct medial eyelid laxity in floppy eyelid syndrome: a new surgical approach. *Ophthal Plast Reconstr Surg*. 2005 Jul; 21(4):259-63.
- Rizvi M, Lypka M, Gaon M, et al. A simplified lateral canthopexy technique. *Plast Reconstr Surg*. 2010 Jun;125(6):248e-249e.
- Shaw LT, Phelps PO. The basics of brow ptosis. *Dis Mon*. 2020 Oct;66(10):101038.
- Velasco Cruz AA, Tibeiro SFT, Garcia DM, et al. Graves upper eyelid retraction. *Survey of Ophthalmology*, 2013-01-01, Volume 58, Issue 1, Pages 63-76.

## Policy History/Revision Information

Date	Summary of Changes
10/01/2024	<p><b>Related Policies</b></p> <ul style="list-style-type: none"> <li>Added reference link to the Medical Policy titled <i>Gender Dysphoria Treatment</i></li> </ul> <p><b>Coverage Rationale</b></p> <ul style="list-style-type: none"> <li>Replaced language indicating “Internal Browpexy is <i>not considered reconstructive</i> and is not medically necessary <i>as it does not correct a functional impairment</i>” with “Internal Browpexy for any condition is considered cosmetic and not medically necessary”</li> <li>Revised coverage criteria for: <ul style="list-style-type: none"> <li><b>Lid Retraction Surgery</b> <ul style="list-style-type: none"> <li>Removed criterion requiring “clear, high-quality, clinical photographs document the pathology”</li> </ul> </li> <li><b>Canthoplasty/Canthopexy</b> <ul style="list-style-type: none"> <li>Removed criterion requiring “clear, high-quality, clinical photographs document the pathology”</li> </ul> </li> <li><b>Floppy Eyelid Syndrome (FES)</b> <ul style="list-style-type: none"> <li>Replaced criterion requiring “other causes of the eye findings have been ruled out” with “infections of the eye have been ruled out”</li> <li>Revised list of examples of infections of the eye: <ul style="list-style-type: none"> <li>Replaced “contact lens (CL) complication” with “contact lens (CL) complication [e.g., giant papillary conjunctivitis (GPC)]”</li> <li>Removed: <ul style="list-style-type: none"> <li>Dermatochalasis</li> <li>Ectropion</li> <li>GPC that is not related to FES</li> <li>Ptoisis of the lid(s)</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> <p><b>Medical Records Documentation Used for Reviews</b> (previously titled <i>Documentation Requirements</i>)</p> <ul style="list-style-type: none"> <li>Replaced list of <i>Required Clinical Information</i> with instruction to refer to the protocol titled <a href="#">Medical Records Documentation Used for Reviews</a></li> </ul> <p><b>Definitions</b></p> <ul style="list-style-type: none"> <li>Added definition of: <ul style="list-style-type: none"> <li>Canthopexy</li> <li>Canthoplasty</li> <li>Lagophthalmos</li> </ul> </li> <li>Removed definition of: <ul style="list-style-type: none"> <li>Congenital Anomaly</li> <li>Cosmetic</li> <li>Cosmetic Procedures (California only)</li> <li>Functional or Physical or Physiological Impairment</li> <li>Reconstructive Procedures</li> <li>Visual Field Testing</li> </ul> </li> <li>Updated definition of: <ul style="list-style-type: none"> <li>Floppy Eyelid Syndrome (FES)</li> <li>Internal Browpexy</li> <li>Marginal Reflex Distance -1 (MRD-1)</li> </ul> </li> </ul> <p><b>Supporting Information</b></p> <ul style="list-style-type: none"> <li>Updated <i>Clinical Evidence</i> and <i>References</i> sections to reflect the most current information</li> <li>Archived previous policy version MP.002.23</li> </ul>

## Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates.



UnitedHealthcare reserves the right to modify its Policies and Guidelines, as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](#)).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.